- Home
- MCRB vs ATOS Comparison
MCRB vs ATOS Comparison
Compare MCRB & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ATOS
- Stock Information
- Founded
- MCRB 2010
- ATOS 2009
- Country
- MCRB United States
- ATOS United States
- Employees
- MCRB N/A
- ATOS N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- ATOS Health Care
- Exchange
- MCRB Nasdaq
- ATOS Nasdaq
- Market Cap
- MCRB 125.7M
- ATOS 107.2M
- IPO Year
- MCRB 2015
- ATOS 2012
- Fundamental
- Price
- MCRB $13.99
- ATOS $0.82
- Analyst Decision
- MCRB Hold
- ATOS Strong Buy
- Analyst Count
- MCRB 4
- ATOS 3
- Target Price
- MCRB $73.67
- ATOS $6.17
- AVG Volume (30 Days)
- MCRB 148.0K
- ATOS 1.4M
- Earning Date
- MCRB 08-06-2025
- ATOS 08-15-2025
- Dividend Yield
- MCRB N/A
- ATOS N/A
- EPS Growth
- MCRB N/A
- ATOS N/A
- EPS
- MCRB 8.98
- ATOS N/A
- Revenue
- MCRB N/A
- ATOS N/A
- Revenue This Year
- MCRB N/A
- ATOS N/A
- Revenue Next Year
- MCRB N/A
- ATOS N/A
- P/E Ratio
- MCRB $1.53
- ATOS N/A
- Revenue Growth
- MCRB N/A
- ATOS N/A
- 52 Week Low
- MCRB $6.53
- ATOS $0.55
- 52 Week High
- MCRB $27.40
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- MCRB 58.12
- ATOS 44.93
- Support Level
- MCRB $12.15
- ATOS $0.84
- Resistance Level
- MCRB $15.40
- ATOS $0.98
- Average True Range (ATR)
- MCRB 1.36
- ATOS 0.05
- MACD
- MCRB -0.12
- ATOS -0.01
- Stochastic Oscillator
- MCRB 65.29
- ATOS 7.65
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.